Yep their plug & play switcheroo on Rexista tells us that for whatever reason the likelihood of securing a partner on Rexista or Regabatin is all but dead unless and until IPCI can hopefully somehow find a way to get Rexista FDA approved some future day.
So that's why there's ZERO value placed on Rexista, Regabatin, PODRAS or any of the other 20 opioid based NDA's claimed to be in their pipeline.
And the reason there's ZERO value placed on their generics division is because almost 9 years since going public...IPCI has only been able to receive FDA approval on 4 ANDA's...2 of which are sitting on a shelf collecting dust...and the 2 that are now finally fully commercialized are delivering nowhere near the expected revenue in the previously expected timeline!
So imo only the main reasons we continue floundering at sub $1 share prices is because the shorts already won here and can now use the $1 minimum share price and $35M minimum market cap NAZ listing requirements as their new fear tool...and if the shorts so choose...they can easily probably force Odidi into doing another raise sometime next year...which will result in IPCI eventually having to do a small reverse split in order to maintain their listing on the Nasdaq Exchange...because quite frankly the past 3 and a half years have clearly proven that Dr. Odidi is incapable of fighting back and garnering support/belief from deep pocketed institutional types...which is the only thing that will ever propel IPCI's share price to much higher ground.
News 
Market Data 
Discover 
